Literature DB >> 29395621

Current practices in clinical neurofeedback with functional MRI-Analysis of a survey using the TIDieR checklist.

Elizabeth Randell1, Rachel McNamara2, Leena Subramanian3, Kerenza Hood2, David Linden3.   

Abstract

BACKGROUND: A core principle of creating a scientific evidence base is that results can be replicated in independent experiments and in health intervention research. The TIDieR (Template for Intervention Description and Replication) checklist has been developed to aid in summarising key items needed when reporting clinical trials and other well designed evaluations of complex interventions in order that findings can be replicated or built on reliably. Neurofeedback (NF) using functional MRI (fMRI) is a multicomponent intervention that should be considered a complex intervention. The TIDieR checklist (with minor modification to increase applicability in this context) was distributed to NF researchers as a survey of current practice in the design and conduct of clinical studies. The aim was to document practice and convergence between research groups, highlighting areas for discussion and providing a basis for recommendations for harmonisation and standardisation.
METHODS: The TIDieR checklist was interpreted and expanded (21 questions) to make it applicable to neurofeedback research studies. Using the web-based Bristol Online Survey (BOS) tool, the revised checklist was disseminated to researchers in the BRAINTRAIN European research collaborative network (supported by the European Commission) and others in the fMRI-neurofeedback community.
RESULTS: There were 16 responses to the survey. Responses were reported under eight main headings which covered the six domains of the TIDieR checklist: What, Why, When, How, Where and Who.
CONCLUSIONS: This piece of work provides encouraging insight into the ability to be able to map neuroimaging interventions to a structured framework for reporting purposes. Regardless of the considerable variability of design components, all studies could be described in standard terms of diagnostic groups, dose/duration, targeted areas/signals, and psychological strategies and learning models. Recommendations are made which include providing detailed rationale of intervention design in study protocols.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Keywords:  Neuroimaging; Psychiatric disorder; fMRI

Mesh:

Year:  2018        PMID: 29395621     DOI: 10.1016/j.eurpsy.2017.10.011

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  5 in total

1.  Control freaks: Towards optimal selection of control conditions for fMRI neurofeedback studies.

Authors:  Bettina Sorger; Frank Scharnowski; David E J Linden; Michelle Hampson; Kymberly D Young
Journal:  Neuroimage       Date:  2018-11-10       Impact factor: 6.556

2.  Infection control link nurse programs in Dutch acute care hospitals; a mixed-methods study.

Authors:  Mireille Dekker; Rosa van Mansfeld; Christina Vandenbroucke-Grauls; Martine de Bruijne; Irene Jongerden
Journal:  Antimicrob Resist Infect Control       Date:  2020-02-27       Impact factor: 4.887

3.  A systematic review of fMRI neurofeedback reporting and effects in clinical populations.

Authors:  Anita Tursic; Judith Eck; Michael Lührs; David E J Linden; Rainer Goebel
Journal:  Neuroimage Clin       Date:  2020-11-11       Impact factor: 4.881

Review 4.  Quality and denoising in real-time functional magnetic resonance imaging neurofeedback: A methods review.

Authors:  Stephan Heunis; Rolf Lamerichs; Svitlana Zinger; Cesar Caballero-Gaudes; Jacobus F A Jansen; Bert Aldenkamp; Marcel Breeuwer
Journal:  Hum Brain Mapp       Date:  2020-04-25       Impact factor: 5.038

5.  Real-Time Functional Magnetic Resonance Imaging Neurofeedback for the Relief of Distressing Auditory-Verbal Hallucinations: Methodological and Empirical Advances.

Authors:  Clara Humpston; Jane Garrison; Natasza Orlov; André Aleman; Renaud Jardri; Charles Fernyhough; Paul Allen
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.